This study was published by the journal of Clinical Microbiology and Infection last May 1, 2021.

Using reports from the World Health Organization (WHO)’s VigiBase, the researchers assessed the increased risk of bradycardia among COVID-19 patients who were exposed to remdesevir. The analysis included all reports of COVID-19 patients registered until September 23, 2020.

The researchers found that among the 2,603 reports of COVID-19 patients prescribed with remdesevir, 302 developed cardiac adverse effects, 94 (or 31%) of which are bradycardia. Of the 94 cases of bradycardia, 80% were serious cases, and 16 were fatal. Compared with hydroxychloroquine (HCQ), lopinavir/ritonavir, tocilizumab, or glucocorticoids, the use of remdesivir was associated with a higher risk of reporting bradycardia.

Editor’s Note: Take note that this report only included reports until September 2020. Meanwhile, in November 2020, the WHO issued a statement advising against the use of remdesevir which cited “the remaining possibility of important harm, as well as the relatively high cost and resource implications associated with remdesivir”. Did the WHO know about the danger behind remdesevir? If yes, then why did it continue to allow countries like the Philippines and India to import the drug? If no, then why didn’t it know when it continued to receive adverse effects following the use of the drug?

This article drives home the point that perhaps our countries should not be so reliant on the WHO after all [we commend India for pushing back against WHO recommendations, see India Bar Association issue cease and desist notice to WHO chief scientist]. The WHO has been so adamant at dissuading countries from using low-risk treatments like HCQ and ivermectin, but has been so lenient at approving dangerous, experimental products like remdesivir and the COVID vaccines. It is clear that the WHO is nothing more than a mouthpiece for Big Pharma companies. Our health and safety are not the WHO’s top priority.

Read Original Article